In the treatment of atrial fibrillation or flutter, the class III antiarrhythmic drug dronedarone is safe and effectively delays recurrence in patients regardless of whether they have undergone cardioversion or not, according to a posthoc analysis presented at the European Society of Cardiology (ESC) Congress 2019.
An edoxaban-based dual antithrombotic therapy (DAT) was noninferior to a VKA*-based triple AT (TAT) in terms of bleeding events at 12 months in patients with atrial fibrillation (AF) following a successful PCI**, without compromising the antithrombotic’s efficacy in preventing ischaemic events, the ENTRUST-AF PCI*** study shows.
Caffeine consumption does not increase the risk of chronic kidney disease (CKD) or affect kidney function, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019), held in Paris, France.
Use of aspirin in the primary prevention of cardiovascular disease (CVD) in patients with no prior CVD history yields protection against the risks of acute myocardial infarction (AMI) and ischaemic stroke, but at the expense of an increase of similar magnitude in the incidence of major bleeding, according to the results of a recent meta-analysis presented at the European Society of Cardiology (ESC) Congress 2019 in Paris, France.
Angina in patients with a history of myocardial infarction (MI) is associated with a higher rate of cardiovascular (CV) death or nonfatal MI, according to late-breaking results from the CLARIFY registry presented at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.
Dapagliflozin consistently reduced the composite outcome of cardiovascular (CV) death and HHF* in patients with type 2 diabetes (T2D) regardless of kidney function, with the greatest benefit seen in those with both reduced eGFR and albuminuria, new insights from the DECLARE-TIMI 58 trial revealed.
The use of guideline-recommended secondary preventive medications is high early after coronary artery bypass grafting (CABG), but declines significantly over time, according to late-breaking results from the SWEDEHEART registry presented at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.
Complete revascularization has been shown to be superior to culprit-lesion-only percutaneous coronary intervention (PCI) in reducing major cardiovascular (CV) events, according to results of the COMPLETE trial reported at the European Society of Cardiology (ESC) Congress 2019 and World Congress of Cardiology (WCC) 2019.
Rivaroxaban monotherapy offers noninferior efficacy and superior safety compared with its combination with an antiplatelet agent in the treatment of patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), results of the Japanese AFIRE trial have shown.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.